- Two new studies raise enough questions about a possible link between childhood cancer and light therapy for newborn jaundice that clinicians should exercise caution in prescribing the treatment for infants whose jaundice is likely to resolve on its own, according to an editorial published in the journal Pediatrics. The suggestion of a link, however, should not deter use of the treatment, also known as phototherapy, in babies who otherwise would be at risk of brain damage or hearing loss.
Tags: ChildhoodCancer, Leukemia
- Dana-Farber physician-researchers report in a new study that the CDK inhibitor abemaciclib yielded encouraging and durable results against several different types of cancers, including breast cancer, lung cancer, glioblastoma, and melanoma.
Tags: BreastCancer, LungCancer, Melanoma
- MatchMiner, an open computational platform developed at Dana-Farber Cancer Institute for matching patient-specific genomic profiles to precision cancer medicine clinical trials, has been named the winner of the Precision Trials Challenge.
Tags: BasicResearch, Genomics
- Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber report in a new study.
Tags: BasicResearch, Immunotherapy
- A new study by Dr. Rachel Freedman finds that breast cancer patients who understood characteristics of their own tumor were more likely to receive recommended therapies.
Tags: BreastCancer, PatientEducation
- Dana-Farber Cancer Institute has been named to Becker's Hospital Review’s 2016 list of "100 Great Hospitals in America."
- Myles Brown, MD, Brown, director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute, has been elected to The National Academy of Sciences.
Tags: Appointments, Honors, Genetics
- Dana-Farber is teaming up with Fitbit to test if weight loss can help prevent breast cancer recurrence among overweight women with early stage disease. This first of its kind study has potential to create a new standard of treatment for millions of breast cancer patients around the world.
Tags: BreastCancer, Exercise
- Study shows patients with relapsed, treatment-resistant multiple myeloma responded better to a combination of ixazomib, lenalidomide, and dexamethasone than to lenalidomide and dexamethasone alone.
Showing 1-10 of 689 items